Abstracts tagged "autoimmune diseases"

Abstract Number: 1596 • ACR Convergence 2021
Changes in Patient-Reported Outcome (PRO) Scores During the COVID-19 Pandemic: Data from the ArthritisPower Research Registry
Kelly Gavigan¹, Esteban Rivera¹, Jeffrey Curtis², Shilpa Venkatachalam¹, Laura Stradford³, David Curtis¹ and William Nowell¹, ¹Global Healthy Living Foundation, Upper Nyack, NY, ²Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ³Global Healthy Living Foundation, Nyack, NY
Background/Purpose: The COVID-19 pandemic caused particular concern among patients with autoimmune and rheumatic disease (ARD) due to increased risk of infection, and heightened sense of…
Abstract Number: 1744 • ACR Convergence 2021
Improvement of Renal and Non-Renal SLE Outcome Measures on Sirolimus Therapy – a 21-year Follow-up Study of 73 Patients
Paramarajan Piranavan¹ and Andras Perl², ¹SUNY Upstate Medical University, Syracuse, NY, ²State University of New York, Syracuse, NY
Background/Purpose: The clinical heterogeneity of the SLE makes it often challenging for the treating clinician and also remains one of the many reasons behind failed…
Abstract Number: 0095 • ACR Convergence 2021
Risk Factors for “Long Haul” COVID-19 in Rheumatology Outpatients in New York City
Medha Barbhaiya¹, Deanna Jannat-Khah¹, Jonah Levine¹, Huong Do¹, Jessica Gordon¹, Vivian Bykerk² and Lisa Mandl¹, ¹Hospital for Special Surgery, New York, NY, ²Division of Rheumatology, Hospital for Special Surgery, New York City, NY
Background/Purpose: COVID-19 ‘long-haulers’ are individuals who experience persistent symptoms after COVID-19 diagnosis. Whether this is of particular concern for rheumatic disease patients, due to their…
Abstract Number: 0189 • ACR Convergence 2021
Tapering and Discontinuation of Background Therapies During the Transition to Rilonacept Monotherapy in RHAPSODY, a Phase 3 Clinical Trial of Rilonacept in Patients with Recurrent Pericarditis
Antonio Brucato¹, Alistair Wheeler², Sushil A. Luis³, Antonio Abbate⁴, Paul Cremer⁵, Fang Fang⁶, Antonella Insalaco⁷, Martin LeWinter⁸, Basil S. Lewis⁹, David Lin¹⁰, Stephen J. Nicholls¹¹, Allan Klein⁵, Massimo Imazio¹² and John F Paolini⁶, ¹Department of Biomedical and Clinical Science, University of Milano, Fatebenefratelli Hospital, Milan, Italy, ²Kiniksa Pharmaceuticals, Ltd., Hamilton, Bermuda, ³Division of Cardiovascular Ultrasound, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, NY, ⁴VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, ⁵Department of Cardiovascular Imaging, Center for the Diagnosis and Treatment of Pericardial Diseases, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, ⁶Kiniksa Pharmaceuticals Corp., Lexington, MA, ⁷Department of Pediatric Medicine, Division of Rheumatology, Bambino Gesù Children's Hospital, Rome, Italy, ⁸Cardiology Unit, The University of Vermont Medical Center, The University of Vermont, Burlington, VT, ⁹Cardiovascular Clinical Research Institute, Lady Davis Carmel Medical Center, Haifa, Israel, ¹⁰Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN, ¹¹MonashHeart, Department of Cardiology, Monash University, Clayton, Australia, ¹²University Cardiology, Cardiovascular and Thoracic Department, AOU Città della Salute e della Scienza di Torino, Torino, Italy
Background/Purpose: Post-episode tapering of Standard of Care (SoC) medication in patients with recurrent pericarditis (RP) varies considerably. Gradual tapering of corticosteroids (CS) is recommended in…
Abstract Number: 0440 • ACR Convergence 2021
Association Between Rheumatic Autoantibody Positivity and Immune-related Adverse Events
Kristen Mathias¹, Marco Lopez Velazquez¹ and Pankti Reid², ¹University of Chicago, Chicago, IL, ²University of Chicago Medical Center, Chicago, IL
Background/Purpose: The advent of immune checkpoint inhibitors (ICIs) has revolutionized cancer therapy; however, their use can lead to off-target toxicities called immune-related adverse events (irAEs)…
Abstract Number: 0650 • ACR Convergence 2021
Use, Procurement Cost, and Adverse Events from IVIg Use in Rheumatic Disease
Francisca Lambert-Fliszar¹, Evelyne Vinet², Sasha Bernatsky¹ and Arielle Mendel³, ¹McGill University, Montréal, QC, Canada, ²McGill University Health Centre, Mont Royal, QC, Canada, ³McGill University Health Centre, Montréal, QC, Canada
Background/Purpose: Intravenous immunoglobulin (IVIg) is used in several systemic rheumatic diseases due to postulated immunomodulatory properties. However, IVIg is a scarce and costly resource and…
Abstract Number: 0993 • ACR Convergence 2021
The Mechanistic Basis of anti-CD6 as a Novel Form for the Treatment of Autoimmune Diseases and Cancer
Mikel Gurrea-Rubio¹, Jeffrey Ruth¹, Qi Wu¹, Eliza Pei-Suen Tsou¹, Phillip Campbell¹, Peggy Randon¹, M.Asif Amin¹, Nora Singer², Feng Lin³ and David Fox¹, ¹University of Michigan, Ann Arbor, MI, ²The MetroHealth System, Cleveland, OH, ³Cleveland Clinic, Cleveland, OH
Background/Purpose: The use of Immune Checkpoint Inhibitors (ICIs) is limited by the induction of immune-related adverse events. CD6 is expressed by most T lymphocytes and…
Abstract Number: 1117 • ACR Convergence 2021
Ocular Scleral Pathology: Clinical Features and Systemic Treatment in 175 Patients from a Single University Center
Lara Sánchez-Bilbao¹, Vanesa Calvo-Río², José Luis Martin-Varillas³, Carmen Álvarez-Reguera¹, Alba Herrero-Morant¹, Iñigo Gonzalez-Mazon⁴, Rosalia Demetrio-Pablo¹, Miguel Ángel gonzalez-Gay⁵ and Ricardo Blanco², ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Hospital Sierrallana, Torrelavega, Spain, ⁴H. U. Marques de Valdecilla, Santander, Spain, ⁵Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: Ocular scleral pathology (OSP) includes episcleritis and scleritis. Episcleritis is generally a benign disease with a self-limited course, while scleritis is a more severe…
Abstract Number: 1511 • ACR Convergence 2021
Investigation of Antigen Specific CD4+ T Cells in Patients with Idiopathic Inflammatory Myopathies
Begum Horuluoglu¹, Angeles Shunashy Galindo-Feria², Karine Chemin³, Genadiy Kozhukh⁴, Anatoly Dubnovitsky⁴, Vivianne Malmström⁵ and Ingrid E Lundberg⁶, ¹Karolinska Institutet, Stockholm, Sweden, ²Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ³Division of Rheumatology, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Science for Life Laboratory, Karolinska Institutet, Stockholm, Sweden, ⁵Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ⁶Karolinska Institutet, Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose: Idiopathic inflammatory myopathies (IIM) also known as myositis, are rare chronic autoimmune disorders represented by lesions in muscle, skin and lung. One of the…
Abstract Number: 1601 • ACR Convergence 2021
Satisfaction with Telemedicine in Immunosuppressed Children and Young Adults with Autoimmune Disease During the COVID 19 Pandemic: Are Their Needs Really Met? Preliminary Data from a Single Institution
Lakshmi Moorthy¹, Lauren Freidenrich¹, Lisa Mikesell², Sarah Fadem², Vikram Bhise¹, Richard Brodsky¹, Ellen Cahill¹, Joann Carlson¹, Yue Hao¹, Daniel Horton¹, Vivien Hsu¹, Editt Rodriguez¹, Christian Salazar³, Cynthia Salvant¹ and Lawrence Kleinman¹, ¹Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²Rutgers Department of Communication, New Brunswick, NJ, ³NYU Dept. of Epi. and Health Promotion, New York, NY
Background/Purpose: COVID-19 can lead to severe and life-threatening complications, which is particularly unnerving for patients with autoimmune disease (AID) on immunosuppressive therapy. Telemedicine has enabled…
Abstract Number: 1746 • ACR Convergence 2021
Baricitinib Decreases Anti-dsDNA and IgG Antibodies in Adults with Systemic Lupus Erythematosus from a Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial
Thomas Dörner¹, Ronald Van Vollenhaven², Andrea Doria³, Bochao Jia⁴, Damiano Fantini⁴, Jorge Ross Terres⁴, Maria Silk⁵, Stephanie de Bono⁴, Peter Fischer⁶ and Daniel Wallace⁷, ¹Charite Universitätsmedizin Berlin and Deutsches Rheumaforschungszentrum (DRFZ), Berlin, Germany, ²University Medical Center, Amsterdam, Netherlands, ³University of Padova, Padova, Italy, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Eli Lilly and Company, Carmel, IN, ⁶Eli Lilly and Company, North Easton, MA, ⁷Cedars-Sinai, Los Angeles, CA
Background/Purpose: Baricitinib (BARI), an oral, selective Janus kinase (JAK)1 and JAK2 inhibitor, improved disease activity in adults with systemic lupus erythematosus (SLE) receiving standard background…
Abstract Number: 0098 • ACR Convergence 2021
Patients with Chronic Inflammatory Rheumatic Diseases Report a Lower Frequency of Infections Than Controls and They Protect Themselves Well Against SARS-CoV-2 Transmission
Iulia Roman, Ioana Andreica, Xenofon Baraliakos, Uta Kiltz and Juergen Braun, Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany
Background/Purpose: The SARS-CoV-2 pandemic has affected life in most countries around the world for more than a year now. It is not entirely clear if…
Abstract Number: 0202 • ACR Convergence 2021
Variables Associated with Response to Therapy in Patients with Interstitial Pneumonia with Autoimmune Features
Elena Joerns¹, Traci Adams¹, Chad Newton¹, Lesley Davila², Kiran Batra¹, Jose Torrealba¹, Craig Glazer¹, Joan Reisch¹, Bonnie Bermas³, David Karp² and Una Makris⁴, ¹UT Southwestern, Dallas, TX, ²UT Southwestern Medical Center, Dallas, TX, ³UTSouthwestern Medical Center, Dallas, TX, ⁴UT Southwestern Medical Center, Dallas Veterans Administration, Dallas, TX
Background/Purpose: We have limited knowledge of the characteristics of patients with interstitial pneumonia with autoimmune features (IPAF) that are associated with response to immunosuppression. Thus,…
Abstract Number: 0444 • ACR Convergence 2021
COVID-19 Vaccination in Autoimmune Disease (CoVAD) Study: Interim Analysis of Safety in Idiopathic Inflammatory Myopathies from a Large Multicentre Global Survey
Latika Gupta¹, James Lilleker², Vishwesh Agarwal³, Sinan Kardes⁴, Marcin Milchert⁵, Tamer Gheita⁶, Babur Salim⁷, Tsvetelina Velikova⁸, Oliver Distler⁹, Hector Chinoy¹⁰, Vikas Aggarwal¹ and Rohit Aggarwal¹¹, ¹Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India, ²Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, The University of Manchester, Centre for Musculoskeletal Research,, Manchester, United Kingdom, ³Mahatma Gandhi Mission Medical College, Navi Mumbai, India, ⁴Medical Ecology and Hydroclimatology Istanbul Faculty of Medicine, Istanbul, Turkey, ⁵Katedra Reumatologii i Chorób Wewnętrznych, Klinika Chorób Wewnętrznych Reumatologii Diabetologii Geriatrii i Immunologii Klinicznej PUM, ul. Unii Lubelskiej 1, 71-252 Szczecin,, Szczecin, Poland, ⁶Cairo University, Egypt, Cairo, Egypt, ⁷Fauji Foundation Hospital, Rawalpindi, Pakistan, ⁸University Hospital Lozenetz, Sofia, Bulgaria, ⁹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich/University of Zurich, Zurich, Switzerland, ¹⁰University of Manchester, Salford, United Kingdom, ¹¹University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Numerous Covid-19 vaccines have demonstrated efficacy and safety against SARS-CoV-2 in general population. Despite favorable adverse effect (ADRs) profile of vaccines, there have been…
Abstract Number: 0651 • ACR Convergence 2021
Diagnostic Approach to Identifying Small Fiber Neuropathy in Patients with Sarcoidosis
Bassel Bou Dargham¹, Nima Madanchi², Kelsey Satkowiak¹, Huzaefah Syed¹ and Kelly Gwathmey³, ¹Virginia Commonwealth University Medical Center, RICHMOND, VA, ²Virginia CommonHealth University Medical Center, Richmond, VA, ³Virginia Commonwealth University Health system, Richmond, VA
Background/Purpose: Sarcoidosis is a multisystem granulomatous disease that can affect the nervous system in about 5% of patients. Sarcoidosis associated small fiber neuropathy (SSFN) presents…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].